Analysis Of Effect Of Recombinant Human Tum Necrosis Factor Receptor In The Treatment Of Plaque Psoriasis On PASI Score

Object: To evaluate the effect of recombinant human tumor necrosis factor receptor(rh TNFR:Fc) in the treatment of moderate to severe plaque psoriasis on psoriasis area and severity index(PASI).Methods: This study collected clinical data of 42 cases of moderate to severe plaque psoriasis patients in the Affiliated Hospital of Shihezi University between January 2011 and March2014, of which there were 20 cases in trial group and 22 cases in the control group respectively, to evaluate the effect on PASI.Results:1.General condition 25 of 42 cases in moderate to severe plaque psoriasis patients were males,the females were 17 cases, the ratio between male and female is 1.47:1. Aged at 18~62 years old, and the average age is 36.79±12.72.2.Clinical manifestations Almost all of the patients are found varying degrees of erythema,infiltration, desquamation, scales and turgidity involving greater than 10% of the skin surface.41 of 42 cases are pruritus. There are 38 of 42 cases with scalp and hair involvement. There are 13 of 42 cases that affect their nails. 5 of 42 cases are exudation.3.Treatment and curative effect All patients applicated with glucocorticoid treatment and light therapy. 20 of 42 cases are rh TNFR-Fc therapy. 22 of 42 cases are acitretin drugs treatment.42 cases of patients had accomplished the 12-week clinical trial. Effects:Effective rate is100.00% in the trial group. 18 of 20 cases are recovery(90.00%). 2 of 20 cases are effective in treatment(10.00%). 0 of 20 cases take a turn for the better(0.00%). 0 of 20 cases are ineffectiveness(0.00%). Effective rate is 86.36%% in the control group. 12 of 22 cases are recovery(54.54%). 7 of 22 cases are effective in treatment(31.82%).2 of 22 cases take a turn for the better(9.09%).1 of 22 cases are ineffectiveness(4.55%). After 12 weeks the rate of PASI30、PASI60、PASI90 were significantly higher than those of the control group(P<0.05).4.Untoward effectThere are pain and swelling at the injection site,be tolerated and improving with the prolonging of time in 3 patients of the trial group. During treatment,translent atrial fibrillation occurres in 1 case of this group,and improved spontaneously. All cases in this group don’t get tuberculosis(TB) or systemic lupus erythematosus(SLE) or so on. Xerosis cutis and desquamation are found in 16 cases in the control group. Cheilitis is noted in 3 patients of this group. 1 patients of this group feel prickling of the skin. Serum lipid and hepatic lipase of 1case rise. All untoward effect of patients with symptomatic treatment can be well-tolerated by the body,and laboratory indicators gradually return to normal,without influencing the continued treatment.Conclusion:The subcutaneous injection of rh TNER-Fc is safe and efficient for patients.